The three drugs are glucagon-like peptide 1 receptor agonists, a drug class that has seen high demand after popularity trickled from celebrities to the masses on social media clamoring for weight-loss results. In October, #Ozempicweightloss saw more than 85 million views and #ozempic has been seen 227 million times on TikTok. The drug is approved only for Type 2 diabetes, but physicians can prescribe the medication for off-label use, such as weight management.
Since its approval in late 2017, Ozempic accounts for 65.4 percent of the GLP-1 market, according to Trilliant Health.
Between the first quarter of 2020 and the end of 2022, prescription volumes for GLP-1 medications increased 300 percent, according to the analysis; that figure exceeds the rate of diabetes prevalence. A slight majority, or 53.8 percent, of patients with GLP-1 prescriptions have a history of diabetes, the report found.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.